Novel hydroxamic acids incorporating 1-((1H-1,2,3-Triazol-4-yl)methyl)-3-hydroxyimino-indolin-2-ones: synthesis, biological evaluation, and SAR analysis
作者:Do Thi Mai Dung、Pham-The Hai、Duong Tien Anh、Le-Thi-Thu Huong、Nguyen Thi Kim Yen、Byung Woo Han、Eun Jae Park、Yeo Jin Choi、Jong Soon Kang、Van-Thi-My Hue、Sang-Bae Han、Nguyen-Hai Nam
DOI:10.1007/s12039-018-1472-x
日期:2018.6
AbstractA series of seventeen novel hydroxamic acids incorporating 1-((1H-1,2,3-triazol-4-yl)methyl)-3-hydroxyimino-indolin-2-ones was designed and synthesized. Biological evaluation showed that these hydroxamic acids potently inhibited a class-I isoform of HDACs (HDAC2) with \(\hbox IC}_50}\) values in low micromolar range. Several compounds also exhibited good cytotoxicity. Two compounds, 5e and
摘要设计并合成了一系列十七种新型的异羟肟酸,它们结合了1-((1 H -1,2,3-三唑-4-基)甲基)-3-羟基亚氨基-吲哚-2-酮。生物学评估表明,这些异羟肟酸有效抑制了HDAC(HDAC2)的I类同工型,且在低微摩尔范围内具有\(\ hbox IC} _ 50} \)值。几种化合物也表现出良好的细胞毒性。5e和5f这两种化合物在三种人类癌细胞系(包括SW620(结肠癌),PC3(前列腺癌)和AsPC-1(胰腺癌))中,作为最有效的HDAC2抑制剂,其细胞毒性比SAHA强8倍。已经进行了分子建模方法,揭示了一些结构-活性关系。关于吸收,分布,代谢,排泄和毒性(ADMET)的进一步研究表明,化合物5e和5f虽然显示出有效的HDAC2抑制生物活性,但仍具有抗癌化合物的理想特性。 图形概要 引入1-(((1 H -1,2,3-三唑-4-基)甲基)-3-羟基亚氨基-吲哚-2-酮的三组新型异